Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.
Multiple myeloma is a genetically heterogenous disease with a wide variety of characterized genetic aberrations. Until recently, the impact of these aberrations on patient outcome was not known. However, in the last 5-10 years, several genetic markers have been linked to patient outcome. One of the strongest predictors of outcome identified to date is t(4;14)(p16;q32). Although this translocation is tightly linked to chromosome 13 deletions, another poor prognosis marker, it is becoming apparent that the translocation and not the deletion of 13 is the important factor. Unfortunately, despite the known association with outcome, an understanding of the mechanism(s) whereby the translocation contributes to developing and maintaining this aggressive form of myeloma remains elusive.
Keats
Jonathan J
JJ
Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Canada. keats.jonathan@mayo.edu
Reiman
Tony
T
Belch
Andrew R
AR
Pilarski
Linda M
LM
D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D002894:Chromosomes, Human, Pair 4 / Q000235:genetics*; D006579:Heterozygote; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism; D013997:Time Factors
D002352:Carrier Proteins; D012097:Repressor Proteins; D011495:Histone-Lysine N-Methyltransferase; C419586:NSD2 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3